News

AccurKardia revealed it’s been granted U.S. Patent No. 12,620,488 for its proprietary machine learning-based system to identify cardiac amyloidosis from a standard…

INTRODUCTIONAcquired transthyretin amyloidosis (ATTR) represents a rare but recognized complication in recipients of domino liver transplants (DLT) from donors…

AbstractAimsTransthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure with substantial morbidity, mortality, and healthcare utilization. ATTRibute-CM […

The cross-border transfer of machine learning models based on the International Classification of Diseases, 10th revision (ICD-10) for the identification of rare…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure with substantial morbidity, mortality, and healthcare utilization. ATTRibute-…

There are substantial delays from the time of incident heart failure to a diagnosis of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to a new…

AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac AmyloidosisPatent establishes IP across all major amyloidosis subtypes and transforms the standard…

Increased levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with more severe neurological symptoms in people with hereditary…

Potential antibody therapies from AstraZeneca and Regeneron for light chain (AL) amyloidosis had new data at ASCO, raising the prospect of new treatments for the…

AbstractWild-type transthyretin amyloid (ATTRwt) amyloidosis is a systemic, progressive disease that often affects older adults and is characterized by ATTRwt…